High levels of pretreatment tumor IL-6R and serum IL-6 expression have been shown to correlate with a higher rate of tumor recurrence and reduced survival of HNSCC patients, which emphasizes the relevance of inhibiting this signaling pathway to mitigate the risk of recurrence in HNSCC [25, 27]. The gene discussed is IL6R; the disease is head and neck squamous cell carcinoma.